CN103638135A - 清浊益肾胶囊 - Google Patents
清浊益肾胶囊 Download PDFInfo
- Publication number
- CN103638135A CN103638135A CN201310710319.9A CN201310710319A CN103638135A CN 103638135 A CN103638135 A CN 103638135A CN 201310710319 A CN201310710319 A CN 201310710319A CN 103638135 A CN103638135 A CN 103638135A
- Authority
- CN
- China
- Prior art keywords
- radix
- filtrate
- semen
- add
- decoct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 24
- 210000003734 kidney Anatomy 0.000 title abstract description 17
- 210000000582 semen Anatomy 0.000 claims abstract description 34
- 239000002994 raw material Substances 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 50
- 239000000706 filtrate Substances 0.000 claims description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 241000628997 Flos Species 0.000 claims description 18
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000009636 Huang Qi Substances 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 7
- 241001649190 Campsis Species 0.000 claims description 6
- 241000190633 Cordyceps Species 0.000 claims description 6
- 241000600871 Euryale <brittle star> Species 0.000 claims description 6
- 235000006487 Euryale ferox Nutrition 0.000 claims description 6
- 240000008669 Hedera helix Species 0.000 claims description 6
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 6
- 241000195474 Sargassum Species 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 13
- 208000024891 symptom Diseases 0.000 abstract description 6
- 230000007812 deficiency Effects 0.000 abstract description 4
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 abstract 1
- 240000004980 Rheum officinale Species 0.000 abstract 1
- 235000008081 Rheum officinale Nutrition 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 23
- 239000008280 blood Substances 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 15
- 206010030113 Oedema Diseases 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 11
- 201000010099 disease Diseases 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 239000002893 slag Substances 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001794 hormone therapy Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 238000002562 urinalysis Methods 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000022461 Glomerular disease Diseases 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000005665 thrombophilia Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010017815 Gastric perforation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000003623 Hypoalbuminemia Diseases 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940125698 hormone suppressant Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 治愈 | 好转 | 未愈 | 总有效率 |
对照组 | 19 | 15 | 12 | 73.9% |
实施例1组 | 24 | 18 | 3 | 93.4% |
实施例2组 | 28 | 17 | 0 | 100% |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310710319.9A CN103638135B (zh) | 2013-12-22 | 2013-12-22 | 清浊益肾胶囊 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310710319.9A CN103638135B (zh) | 2013-12-22 | 2013-12-22 | 清浊益肾胶囊 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103638135A true CN103638135A (zh) | 2014-03-19 |
CN103638135B CN103638135B (zh) | 2016-01-20 |
Family
ID=50243507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310710319.9A Active CN103638135B (zh) | 2013-12-22 | 2013-12-22 | 清浊益肾胶囊 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103638135B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106728081A (zh) * | 2016-12-27 | 2017-05-31 | 翔宇药业股份有限公司 | 清浊益肾胶囊的制备及质量标准检验方法 |
CN111840385A (zh) * | 2020-08-31 | 2020-10-30 | 翔宇药业股份有限公司 | 清浊益肾胶囊及其生产工艺 |
CN112168804A (zh) * | 2020-11-04 | 2021-01-05 | 翔宇药业股份有限公司 | 清浊益肾胶囊的制备及质量标准检验方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1466963A (zh) * | 2002-07-11 | 2004-01-14 | 山东百草药业有限公司 | 一种治疗肾病的肾舒胶囊及其制备方法 |
CN1481891A (zh) * | 2002-09-09 | 2004-03-17 | 贾在金 | 一种治疗慢性肾功能衰竭的药物 |
CN101862379A (zh) * | 2009-04-20 | 2010-10-20 | 张天良 | 一种治疗肾功能衰竭的中药 |
-
2013
- 2013-12-22 CN CN201310710319.9A patent/CN103638135B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1466963A (zh) * | 2002-07-11 | 2004-01-14 | 山东百草药业有限公司 | 一种治疗肾病的肾舒胶囊及其制备方法 |
CN1481891A (zh) * | 2002-09-09 | 2004-03-17 | 贾在金 | 一种治疗慢性肾功能衰竭的药物 |
CN101862379A (zh) * | 2009-04-20 | 2010-10-20 | 张天良 | 一种治疗肾功能衰竭的中药 |
Non-Patent Citations (1)
Title |
---|
国家食品药品监督管理局: "《国家中药品种选编》", 31 January 2005, article "清浊益肾胶囊", pages: 188 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106728081A (zh) * | 2016-12-27 | 2017-05-31 | 翔宇药业股份有限公司 | 清浊益肾胶囊的制备及质量标准检验方法 |
CN106728081B (zh) * | 2016-12-27 | 2020-06-19 | 翔宇药业股份有限公司 | 清浊益肾胶囊的制备方法 |
CN111840385A (zh) * | 2020-08-31 | 2020-10-30 | 翔宇药业股份有限公司 | 清浊益肾胶囊及其生产工艺 |
CN112168804A (zh) * | 2020-11-04 | 2021-01-05 | 翔宇药业股份有限公司 | 清浊益肾胶囊的制备及质量标准检验方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103638135B (zh) | 2016-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102028900B (zh) | 一种治疗代谢综合征的中药及其制备方法 | |
CN103006979B (zh) | 一种治疗肾病水肿的内服中药组合物 | |
CN1899455B (zh) | 一种治疗小儿热型腹泻的外贴膏及制备方法 | |
CN103638136A (zh) | 虫草芪参胶囊 | |
CN103638135B (zh) | 清浊益肾胶囊 | |
CN101766777B (zh) | 一种治疗慢性肾衰竭的中药组合物 | |
CN101966312B (zh) | 一种治疗慢性肾衰竭的中药组合物的制备方法 | |
CN104800504A (zh) | 一种治疗肾炎的中药制剂及制法 | |
CN101912596A (zh) | 一种治疗过敏性鼻炎的药物及其制备方法 | |
CN101757408A (zh) | 一种***的药物及其制备方法 | |
CN105999058B (zh) | 鬼针草降脂片 | |
CN103920102A (zh) | 一种治疗原发性低血压的中药药物 | |
CN1192789C (zh) | 一种治疗糖尿病的茶及其制备方法 | |
CN106166262A (zh) | 一种治疗慢性肾衰竭的中药组合物 | |
CN101912498A (zh) | 一种治疗痛风的药物及其制备方法 | |
CN105362682A (zh) | 一种治疗月经过少的外用药物 | |
CN104069412B (zh) | 一种防治糖尿病肾病的中药 | |
CN102552674B (zh) | 一种治疗肾病综合征的中药药物 | |
CN102357218B (zh) | 一种治疗***的中药组合物 | |
CN102406854A (zh) | 一种治疗不寐的中药组合物 | |
CN102406913A (zh) | 一种治疗郁证的中药组合物 | |
CN101987162B (zh) | 治疗紫癜性肾炎肾病综合征型的中药制剂 | |
CN105943860A (zh) | 一种用于治疗糖尿病的药物制剂及其制备方法 | |
CN106109839A (zh) | 一种调理脾虚的中药组合物 | |
CN104623387A (zh) | 一种用于治疗慢性肾炎的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHANDONG XIANGYU HEALTH PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LIN FANYOU Effective date: 20140710 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140710 Address after: 276023 No. 30, Hangzhou Road, Linyi economic and Technological Development Zone, Linyi, Shandong Applicant after: Shandong Xiangyu Health Pharmaceutical Co., Ltd. Address before: 276023 Beijing road Shandong Linyi Province, Linyi City Economic Development Zone No. 30 Shandong Xiangyu Health Pharmaceutical Co. Ltd. Applicant before: Lin Fanyou |
|
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 276023 No. 30, Hangzhou Road, Linyi economic and Technological Development Zone, Linyi, Shandong Applicant after: Xiang Yu Pharmaceutical limited company Address before: No. 30, Hangzhou Road, Linyi economic and Technological Development Zone, Shandong, Linyi Applicant before: Shandong Xiangyu Health Pharmaceutical Co., Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SHANDONG XIANGYU HEALTH PHARMACEUTICAL CO., LTD. TO: XIANGYU PHARMACEUTICAL CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |